VIBRA-TABS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VIBRA-TABS (VIBRA-TABS).
Tetracycline antibiotic; inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex.
| Metabolism | Primarily hepatically metabolized; no specific major enzyme pathway identified, but thought to involve oxidative metabolism. |
| Excretion | Renal (40% as unchanged drug via glomerular filtration), biliary/fecal (20-30%, including enterohepatic circulation). |
| Half-life | Terminal elimination half-life: 18-22 hours (single dose); increases to 24-48 hours in renal impairment. Mean half-life after multiple doses: 14-16 hours. |
| Protein binding | 60-80% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | 1.3-1.8 L/kg; indicates extensive tissue penetration (e.g., lung, prostate, bile). |
| Bioavailability | Oral: 95-100% (doxycycline hyclate); food decreases absorption by 20% (no significant effect with Vibra-Tabs formulation). |
| Onset of Action | Oral: 30-60 minutes (therapeutic serum levels at 1-2 hours). |
| Duration of Action | 24 hours (maintained by twice-daily dosing). |
| Molecular Weight | 444.43 |
100 mg orally twice daily on day 1, then 100 mg orally once daily
| Dosage form | TABLET |
| Renal impairment | CrCl >50 mL/min: no adjustment; CrCl 10-50 mL/min: 100 mg every 24 hours; CrCl <10 mL/min: 100 mg every 36 hours |
| Liver impairment | No adjustment required for mild to moderate hepatic impairment; not recommended in severe hepatic impairment (Child-Pugh C) |
| Pediatric use | ≥8 years and >45 kg: 100 mg orally every 12 hours on day 1, then 100 mg orally once daily; ≤45 kg: 4.4 mg/kg on day 1, then 2.2 mg/kg orally once daily; maximum 100 mg/day |
| Geriatric use | Use lowest effective dose; monitor renal function as clearance may be reduced; no specific dose adjustment based on age alone |
| 1st trimester | Tetracycline antibiotics, including doxycycline (Vibra-Tabs), are generally avoided in the first trimester due to potential teratogenic effects and association with fetal skeletal development abnormalities. Use only if no alternative and benefit outweighs risk. |
| 2nd trimester | Contraindicated in the second trimester due to risk of permanent tooth discoloration (yellow-gray-brown) and enamel hypoplasia in the fetus. Also may inhibit fetal bone growth. |
| 3rd trimester | Contraindicated in the third trimester for the same reasons as second trimester: tooth discoloration and bone growth inhibition. |
Clinical note
Comprehensive clinical and safety monograph for VIBRA-TABS (VIBRA-TABS).
| Placental transfer | Doxycycline readily crosses the placenta. It binds to fetal bone and teeth, causing discoloration and potential bone growth retardation. |
| Breastfeeding | Doxycycline is excreted into breast milk in small amounts. However, due to the potential for serious adverse reactions in nursing infants, such as tooth discoloration and bone growth inhibition, alternative agents are preferred. The American Academy of Pediatrics recommends using with caution; short-term use (less than 3 weeks) may be acceptable, but avoid prolonged courses. |
■ FDA Black Box Warning
Use during tooth development (last half of pregnancy, infancy, and children up to 8 years) may cause permanent discoloration of teeth (yellow-gray-brown) and enamel hypoplasia. Should not be used in this age group unless other drugs are likely ineffective or contraindicated.
| Serious Effects |
Hypersensitivity to doxycycline or any tetracycline antibioticPregnancy (especially second and third trimesters)Lactation (prolonged use)Children under 8 years of age (due to permanent tooth discoloration)Severe hepatic impairment
| Precautions | Photosensitivity manifested by exaggerated sunburn reaction., May cause pseudomembranous colitis due to Clostridium difficile overgrowth., Hepatotoxicity has been reported; use with caution in patients with hepatic impairment., Renal toxicity: do not use in patients with impaired renal function unless necessary; may increase BUN due to anti-anabolic effect., Overgrowth of non-susceptible organisms including fungi., May cause benign intracranial hypertension (pseudotumor cerebri). |
| Food/Dietary | Absorption is reduced by dairy products (milk, cheese, yogurt) and calcium-fortified foods. Avoid concurrent intake with iron-rich foods or supplements. High-fat meals may decrease absorption; take on an empty stomach if possible, but if gastrointestinal upset occurs, take with a small amount of non-dairy food. Avoid alcohol as it may reduce efficacy and increase hepatotoxicity risk. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - Use only if benefit outweighs risk. Alternative agents preferred. |
| Teratogenic Risk | Tetracycline (active ingredient in Vibra-Tabs) crosses the placenta. First trimester: Avoid due to possible teratogenicity (limb anomalies, neural tube defects) from animal studies, though human data limited. Second and third trimesters: Contraindicated; causes permanent yellow-gray-brown discoloration of deciduous teeth, enamel hypoplasia, and reversible skeletal growth retardation. |
| Fetal Monitoring | Monitor maternal liver and renal function; assess for photosensitivity, pseudotumor cerebri. Fetal monitoring includes ultrasound for skeletal development and tooth mineralization if exposure occurs in second half of pregnancy. |
| Fertility Effects | No known significant effects on fertility in humans. Animal studies show reversible reduced spermatogenesis at high doses. No evidence of ovarian toxicity. |
| Clinical Pearls | Vibra-Tabs (doxycycline hyclate) is a tetracycline antibiotic with high oral bioavailability. Avoid concomitant administration with antacids, iron, calcium, magnesium, or bismuth subsalicylate as they chelate doxycycline and reduce absorption. Administer with a full glass of water to reduce esophageal irritation. Photosensitivity reactions are common; advise sun protection. Use with caution in patients with hepatic impairment or myasthenia gravis. Monitor for pseudomembranous colitis. Doxycycline is not recommended in children under 8 years or during pregnancy/lactation due to risk of permanent tooth discoloration and bone growth inhibition. |
| Patient Advice | Take doxycycline exactly as prescribed, usually once or twice daily. · Swallow tablets whole with a full glass of water; do not crush or chew. · Avoid lying down for at least 30 minutes after taking to prevent esophageal irritation. · Do not take with dairy products, antacids, or supplements containing calcium, magnesium, iron, or zinc within 2 hours before or 6 hours after dosing. · Use effective sun protection (sunscreen, protective clothing) and avoid prolonged sun exposure as this medication increases sensitivity to UV light. · Complete the full course even if you feel better; skipping doses can lead to resistance. · Report any severe diarrhea, skin rash, or difficulty swallowing immediately. · Do not use expired medication as it can cause kidney damage. · Store at room temperature, away from light and moisture. |